reached a $1.95 billion deal with Pfizer and BioNTech for 100 million doses of their experimental COVID-19 vaccine once it obtains Food and Drug Administration approval.An additional 500 million doses can be acquired, and U.S.
citizens would receive the vaccine for free, according to the agreement.RELATED: Who would be the first to get a COVID-19 vaccine?A Phase 2b/3 trial of the vaccine, with human subjects, is scheduled to start later this month and will be subject to regulatory review as early as October 2020.